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INTRODUCTION
Dyspepsia is defined as chronic or recurrent central
upper abdominal pain or discomfort which is referable
to the upper gastrointestinal tract1,2. It is usually
associated with intake of  food or hunger. Discomfort
according to the Rome Working Teams refers to a
subjective, negative feeling that does not reach the level
of pain according to the patient. This can incorporate
a variety of symptoms such as upper abdominal
fullness, early satiety, bloating, belching or nausea1, 2.
Dyspepsia is a common presentation in clinical practice
worldwide1, 2. It has a prevalence of between 20%
and 40% in the adult population 3, 4. In a study carried
out among the British population it was found to be
38%5. It is estimated to account for 2% to 5% of
primary care office visits and 30% of consultations by
Gastroenterologists6, 7. A prevalence of 26% to 45%
was found in some parts of Nigeria8, 9. Dyspepsia has
a significant impact on quality of life10, and results in
enormous societal costs, either due to direct medical
costs for physician visits, diagnostic tests, medications,
or indirect costs from absenteeism or reduced
productivity at work11, 12. It is therefore, important to
explore the management options available in the light
of  the foregoing.
CLASSIFICATION OF DYSPEPSIA
Dyspepsia can be broadly classified into two major
groups. These include organic dyspepsia and functional
dyspepsia.
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Background: Dyspepsia has a significant impact on the quality
of  life of  the sufferer, and results in enormous societal costs,
either due to direct medical costs for physician visits, diagnostic
tests, medications, or indirect costs from absenteeism or reduced
productivity at work. It is therefore important to explore the
management options available, especially in a resource poor
setting like Nigeria, in the light of  the foregoing.
Methods: Extensive internet literature search was made through
Google scholar, Pubmed and HINARI. Keywords employed
were dyspepsia, prevalence and management.
Result: Several approaches proposed for the management of a
newly diagnosed patient with dyspepsia include: empirical trial
of acid suppression for 4-8 weeks in regions with low prevalence
of H. pylori; the “test and treat” approach for H. pylori infection
using a validated non-invasive test and; initial use of upper
gastrointestinal endoscopy to determine the nature of  the disease
before treatment in patients with alarm symptoms and those
who are more than 45 years. Helicobacter pylori eradication
therapy without initial diagnostic testing can be used as the last
result in resource poor regions of the word where diagnostic
tests for H. pylori are not available or not cost-effective.
Conclusion: Considering the high cost of upper gastrointestinal
endoscopy and the high prevalence of H. pylori infection in
developing countries like Nigeria, it seems reasonable that the
‘test and treat’ method will be of immense usefulness in
population sub-group who are less than 45 years without alarm
symptoms, while those with alarm symptoms and those with
onset of symptoms after 45 years will require initial upper
gastrointestinal endoscopy.
Keywords: Dyspepsia, Classification, Pathophysiology and Management.
FEATURE ARTICLE
                                                   Annals of Ibadan Postgraduate Medicine. Vol. 11 No. 1 June, 2013 2
Ann Ibd. Pg. Med 2013. Vol.11, No.1 2-6
Organic dyspepsia: This is dyspepsia that results
from a structural or anatomical lesion. These structural
lesions include chronic gastritis, duodenitis, gastric and
duodenal erosions, gastric and duodenal ulcers, gastric
adenocarcinoma and mucosal associated lymphoid
tissue (MALT) lymphoma.13, 14 Helicobacter pylori infection
has been noted to be associated with most of the
disease entities presenting as dyspepsia.13, 14 The
particular end result of H. pylori infection is determined
by a complex interaction between bacterial, host and
other environmental factors.13 A detailed description
of  this interaction is beyond the scope of  this review.
Functional dyspepsia: This is dyspepsia in which there
is no evidence of organic disease that can adequately
explain the symptoms. It is also known as idiopathic
or non-ulcer dyspepsia, and is often a diagnosis of
exclusion. Many patients with functional dyspepsia (FD)
have multiple somatic complaints, as well as symptoms
of anxiety and depression.15 It is further subdivided
clinically into ulcer-like, reflux-like, dysmotility-like, and
non-specific dyspepsia.16 This sub-grouping, however,
has not been found to be of much practical value in
identifying the underlying cause of dyspepsia as the
symptoms overlap considerably.
The pathophysiology of  functional dyspepsia is poorly
understood. There is symptom overlap with those of
other functional gastrointestinal disorders, such as
functional heartburn, irritable bowel syndrome (IBS),
and non-cardiac chest pain.17 Like other functional
gastrointestinal disorders, FD is best understood in
the context of the bio-psychosocial model of illness
in which symptoms arise out of a complex interaction
between abnormal gastrointestinal physiology and
psychosocial factors that affect how a person perceives,
interprets, and responds to the altered gastrointestinal
physiology.18 Several pathophysiological mechanisms
that have been suggested as playing a part in its
development include delayed gastric emptying,18,19
impaired gastric accommodation,20,21 myoelectric
abnormalities,22,23 altered antro-duodeno-jejunal
motility24, visceral hypersensitivity,25 altered vagal
function,26 altered duodenal sensitivity to lipids or
acid,27, 28 and psychological disorders.29,30
MANAGEMENT
Several approaches that have been proposed for the
management of a newly diagnosed patient with
dyspepsia include:1, 31
1. Empirical trial of acid suppression with
antisecretory drugs like proton pump inhibitor
(PPI) or Histamine 2 receptor blocker for 4-8
weeks
2. The “test and treat” approach for H. pylori infection
using a validated non-invasive test and a trial of
gastric acid suppression if eradication is successful
but symptoms do not resolve, and
3. Initial upper gastrointestinal endoscopy (UGE) to
determine the nature of  the disease.
Empirical trial of acid suppression
This approach is recommended in populations with
low prevalence of H. Pylori infection (<10%).1, 32 It is
done using antisecretory drugs like proton pump
inhibitor (PPI) or Histamine 2 receptor blocker for 4-
8 weeks. If  there is no amelioration of  symptoms
within 2-4 weeks of commencement of treatment, it
is recommended that drug class be changed. Generally,
PPIs have been found to be more effective than the
H2RBs.
Although this approach is cheap, a major drawback
to its use is the generally high prevalence of H. pylori
infection in regions of the world with poor socio-
economic condition.
‘Test and treat’ method
With the burden of evidence implicating H. pylori in
the aetiology of  different diseases manifesting clinically
as dyspepsia, it will be appropriate for all patients with
dyspepsia who are positive for H. pylori to undergo
H. pylori eradication therapy.1,5,9 More so, that H. pylori
eradication has been associated with significant
reduction in rate of recurrence of peptic ulcer disease
and cure of  MALT.13 When there are no ‘alarm
symptoms’ the ‘test and treat’ method using multidrug
therapy for H. pylori eradication is a rational approach,
especially in populations with a moderate to high
prevalence of H. pylori infection (>10%) followed by
a course of empirical antisecretory therapy in patients
who fail to respond or relapse rapidly on stopping H.
pylori eradication therapy. 1, 33, 34
The urea breath test and the stool antigen test are the
recommended tests in non-invasive diagnosis of H.
Pylori because of  their high diagnostic accuracy.35, 36
Serological tests are not recommended because of their
low discriminatory power between old and current
infections. They cannot also be used to ascertain cure
of infection.
One major drawback to this approach in developing
countries like Nigeria is the rarity of these non-invasive
diagnostic tests of choice.
Initial upper gastrointestinal endoscopy
There is controversy as to when UGE should be done
considering the cost and the risks involved.
Nevertheless, UGE is clearly indicated when a patient
with dyspepsia presents with any of the following
features: Presentation with a first episode of dyspepsia
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at >45 years of age (because of risk of malignancy),
failure to respond to empirical anti-secretory therapy,
and presence of  alarm symptoms. 1, 32
Alarm symptoms include anorexia, weight loss,
odynophagia, dysphagia, persistent vomiting,
haematemesis, melaena, anaemia, unexplained weight
loss (>10% body weight), a family history of
gastrointestinal cancer, previous esophagogastric
malignancy, lymphadenopathy, or an abdominal mass.1
A careful history-taking, thorough physical examination
and investigations such as abdominal ultrasound scan,
barium studies, computer tomography and magnetic
resonance imaging may be required for further
characterization of  disease in those who have alarm
symptoms.
For younger patients who do not have alarm
symptoms further diagnostic investigations are not
usually required since upper gastrointestinal malignancy
is rarely present in them, although the positive predictive
value of  alarm features remains very poor. 37
Endoscopy may also be required to reassure patients
who are worried that a malignant condition may be
responsible for their symptoms.1 However, repeat
endoscopy is not recommended once a diagnosis of
non-ulcer dyspepsia has been clearly established in such
patients, unless a completely new set symptoms or
alarm features develop.
Treatment of  endoscopy-negative dyspepsia
(functional dyspepsia)
Endoscopy-proven functional dyspepsia is also treated
with initial antisecretory therapy and H. pylori
eradication just as organic dyspepsia. Management
challenge arises when these measures fail because no
other measure has been found to have optimal
efficacy1.
Simple reassurance as regards the benign nature of
the illness may go a long way to ameliorate patients’
anxiety. Occasionally, a reconsideration of  diagnosis
may be needed in order not to miss other conditions
that may mimic dyspepsia. Dietary therapy may help
some individuals although it has no established efficacy.
Adapted from: Talley NJ, Vakil N. Guidelines for the management of  dyspepsia. Am J Gastroenterol. 2005; 100 (10):2324-2337
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Simethicone, low-dose tricyclic antidepressants and
antispasmodics have all been used but there are very
limited data supporting their efficacy .1
Limited studies support psychotherapy, hypnotherapy,
and cognitive-behavioral therapy but they cannot be
generally recommended for now.1
Helicobacter pylori eradication therapy without
initial diagnostic test
This approach is usually the last result in resource poor
regions of the word where diagnostic tests for H.
pylori are not readily available or diagnostic tests for
the infection are not cost-effective. 38 The decision to
treat is based on the assumption that H. pylori infection
is present in patients with symptoms of dyspepsia since
the prevalence of H. pylori is generally high in such
settings.14, 38 It is therefore better to treat the infection
empirically than to do nothing because of patients’
inability to afford the cost of investigation, considering
the immense benefits accruing to the dyspeptic patient
following eradication of the organism.
The drawback to this approach, however, is that one
cannot say with all certainty that the organism has been
eradicated after treatment.
CONCLUSION
Considering the high cost of UGE and the high
prevalence of H. pylori infection in developing countries
like Nigeria,14, 38 it seems reasonable that the ‘test and
treat’ method using recommended non-invasive tests
will be of immense usefulness in population sub-group
who are less than 45 years of  age without alarm
symptoms, while those with alarm symptoms
irrespective of age and those with onset of symptoms
after 45 years will require initial upper gastrointestinal
endoscopy.
It is highly desirable that the recommended non-
invasive diagnostic tests for H. Pylori, in addition to
the existing gastrointestinal endoscopy facilities, are
made available by policy makers. This will go a long
way to improve the quality of care of patients, save
cost of care and reduce the burden on the already
overburdened Endoscopists and facilities for UGE
in such populations.
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